All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
AML Hub Steering Committee May 2024
During a meeting of the AML Hub Steering Committee, held on May 8, 2024, Jeffrey Lancet chaired a discussion on the question: How can we apply minimal residual disease (MRD) guidelines to low-intensity therapy in acute myeloid leukemia (AML)? The discussion featured contributions from Gail Roboz, Naval Daver, and Uwe Platzbecker.
The steering committee members discuss how MRD negativity can serve as a prognostic tool for guiding treatment decisions in AML, including low-intensity therapy (e.g., hypomethylating agents, venetoclax), maintenance therapy (including gilteritinib), transplantation, treatment modification, and extended drug holidays, in both fit and older/frail patients. The steering committee members highlighted the limitations of existing MRD assessment methods, such as the sensitivity of flow cytometry, assay quality, NPM1, FLT3, NGS PCR assays, and RNA fusion panels. The group also previewed the upcoming European LeukemiaNet risk guidelines on MRD monitoring and potential opportunities to learn about experiences in other diseases, such as acute and chronic lymphoblastic leukemia.
AML Hub Steering Committee May 2024
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox